Literature DB >> 21411555

High growth rate of benign thyroid nodules bearing RET/PTC rearrangements.

Maria Rosaria Sapio1, Anna Guerra, Vincenzo Marotta, Elisabetta Campanile, Raffaele Formisano, Maurilio Deandrea, Manuela Motta, Paolo Piero Limone, Gianfranco Fenzi, Guido Rossi, Mario Vitale.   

Abstract

CONTEXT: Benign thyroid nodules display a broad range of behaviors from a stationary size to a progressive growth. The RET/PTC oncogene has been documented in a fraction of benign thyroid nodules, besides papillary thyroid carcinomas, and it might therefore influence their growth.
OBJECTIVE: The aim of the present work was to evaluate whether RET/PTC in benign thyroid nodules associates with a different nodular growth rate. STUDY
DESIGN: In this prospective multicentric study, 125 subjects with benign nodules were included. RET rearrangements were analyzed in cytology samples; clinical and ultrasonographic nodule characteristics were assessed at the start and at the end of the study.
RESULTS: RET/PTC was present in 19 nodules. The difference between the mean baseline nodular volume of the RET/PTC- and RET/PTC+ nodules was not significant. After 36 months of follow-up, the RET/PTC+ group (n = 16) reached a volume higher than the RET/PTC- group (n = 90) (5.04 ± 2.67 vs. 3.04 ± 2.26 ml; P = 0.0028). We calculated the monthly change of nodule volumes as a percentage of baseline. After a mean follow-up of 36.6 months, the monthly volume increase of nodules bearing a RET rearrangement was 4.3-fold that of nodules with wild-type RET (1.83 ± 1.2 vs. 0.43 ± 1.0% of baseline volume; P < 0.0001).
CONCLUSIONS: Benign thyroid nodules bearing RET rearrangements grow more rapidly than those with wild-type RET. Searching for RET rearrangements in benign thyroid nodules might be useful to the clinician in choosing the more appropriate and timely therapeutic option.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21411555     DOI: 10.1210/jc.2010-1599

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  22 in total

1.  Usefulness of NRAS codon 61 mutation analysis and core needle biopsy for the diagnosis of thyroid nodules previously diagnosed as atypia of undetermined significance.

Authors:  Eun Kyung Jang; Won Gu Kim; Eui Young Kim; Hyemi Kwon; Yun Mi Choi; Min Ji Jeon; Jung Hwan Baek; Jeong Hyun Lee; Tae Yong Kim; Young Kee Shong; Jene Choi; Dong Eun Song; Won Bae Kim
Journal:  Endocrine       Date:  2015-11-07       Impact factor: 3.633

2.  Association between BRAF and RAS mutations, and RET rearrangements and the clinical features of papillary thyroid cancer.

Authors:  Jie Ming; Zeming Liu; Wen Zeng; Yusufu Maimaiti; Yawen Guo; Xiu Nie; Chen Chen; Xiangwang Zhao; Lan Shi; Chunping Liu; Tao Huang
Journal:  Int J Clin Exp Pathol       Date:  2015-11-01

Review 3.  Coding Molecular Determinants of Thyroid Cancer Development and Progression.

Authors:  Veronica Valvo; Carmelo Nucera
Journal:  Endocrinol Metab Clin North Am       Date:  2018-12-23       Impact factor: 4.741

Review 4.  Molecular profiling of thyroid nodule fine-needle aspiration cytology.

Authors:  Markus Eszlinger; Lorraine Lau; Sana Ghaznavi; Christopher Symonds; Shamir P Chandarana; Moosa Khalil; Ralf Paschke
Journal:  Nat Rev Endocrinol       Date:  2017-03-31       Impact factor: 43.330

5.  Relevance of BRAF(V600E) mutation testing versus RAS point mutations and RET/PTC rearrangements evaluation in the diagnosis of thyroid cancer.

Authors:  Martina Rossi; Mattia Buratto; Federico Tagliati; Roberta Rossi; Sabrina Lupo; Giorgio Trasforini; Giovanni Lanza; Paola Franceschetti; Stefania Bruni; Ettore Degli Uberti; Maria Chiara Zatelli
Journal:  Thyroid       Date:  2014-11-24       Impact factor: 6.568

6.  Concomitant RAS, RET/PTC, or BRAF mutations in advanced stage of papillary thyroid carcinoma.

Authors:  Minjing Zou; Essa Y Baitei; Ali S Alzahrani; Faisal S BinHumaid; Dania Alkhafaji; Roua A Al-Rijjal; Brian F Meyer; Yufei Shi
Journal:  Thyroid       Date:  2014-06-10       Impact factor: 6.568

Review 7.  Molecular genetics and diagnosis of thyroid cancer.

Authors:  Yuri E Nikiforov; Marina N Nikiforova
Journal:  Nat Rev Endocrinol       Date:  2011-08-30       Impact factor: 43.330

Review 8.  Molecular pathogenesis and mechanisms of thyroid cancer.

Authors:  Mingzhao Xing
Journal:  Nat Rev Cancer       Date:  2013-03       Impact factor: 60.716

9.  BRAF (V600E) associates with cytoplasmatic localization of p27kip1 and higher cytokeratin 19 expression in papillary thyroid carcinoma.

Authors:  Anna Guerra; Vincenzo Marotta; Maurilio Deandrea; Manuela Motta; Paolo Piero Limone; Alessia Caleo; Pio Zeppa; Silvano Esposito; Franco Fulciniti; Mario Vitale
Journal:  Endocrine       Date:  2012-12-01       Impact factor: 3.633

10.  Evolution of benign thyroid nodules under levothyroxine non-suppressive therapy.

Authors:  Alessandro Puzziello; Mario Carrano; Elisabetta Angrisani; Vincenzo Marotta; Antongiulio Faggiano; Pio Zeppa; Mario Vitale
Journal:  J Endocrinol Invest       Date:  2014-07-10       Impact factor: 4.256

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.